Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer

Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer

(2019) Takayuki Yoshino et al.   JAMA Oncology

A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study

(2018) Eiji Oki et al.   Clinical Colorectal Cancer

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial

(2018) Rui-Hua Xu et al.   LANCET ONCOLOGY

A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer

(2015) Yasushi Sato et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

(2015) Chiara Cremolini et al.   LANCET ONCOLOGY

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

(2014) Fotios Loupakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

(2013) W. Schmiegel et al.   ANNALS OF ONCOLOGY

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer

(2013) F. Loupakis et al.   EUROPEAN JOURNAL OF CANCER

The search for treatments to reduce chemotherapy-induced peripheral neuropathy

(2013) Deirdre R. Pachman et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium and Magnesium to Prevent Oxaliplatin-Induced Sensory Neurotoxicity (N08CB/Alliance)

(2013) Charles L. Loprinzi et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

(2011) G. Perrocheau et al.   ONCOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY